On the other hand, there are significant differences questioning whether FAP-HCA should be added to the subgroup of beta-catenin-activated HCA with conventional exon 3 mutations of the CTNNB1 gene and strong and homogenous GS overexpression. The gene discussed is CTNNB1; the disease is hepatocellular adenoma.